Literature DB >> 1690828

Clonal growth of haemopoietic progenitor cells from myelodysplastic marrow in response to recombinant haemopoietins.

P Baines1, D Bowen, A Jacobs.   

Abstract

The growth factor requirements of granulocyte-macrophage (GM) and erythroid marrow progenitor cells from 12 myelodysplastic (MDS) patients have been analysed. GM progenitors from two of six patients who grew normal numbers of colonies in response to conditioned medium + erythropoietin (5637CM + Epo) showed defective responses to either GMCSF and/or IL-3. Of all the recombinant factors tested (IL-3, IL-1, GCSF, GMCSF, MCSF), GMCSF was the strongest stimulator of myeloid clonal growth, inducing normal numbers of GM colonies from marrow of six patients (two of whom were neutropenic). Erythroid colonies were low in 5637CM + Epo-supplemented cultures of marrow from all but one patient and remained poor in the presence of any of the haemopoietins. tested. Supraoptimal doses (for normal marrow) of these haemopoietins improved colony growth in only one patient (GM colonies in response to IL-3). Combinations of factors were also largely ineffective at raising myeloid or erythroid colony numbers. These data indicate that the defective response of MDS progenitor cells to growth factors is not amenable to experimental manipulation of recombinant factor levels or combinations. Clonal assays might suggest a role for GMCSF therapy in a subpopulation of neutropenic MDS patients but their potential now needs to be evaluated in association with clinical trials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690828     DOI: 10.1016/0145-2126(90)90132-s

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.

Authors:  D Marisavljević; Z Rolović; D Sefer; N Basara; D Ilić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Authors:  Steven M Kornblau; Aileen C Cohen; David Soper; Ying-Wen Huang; Alessandra Cesano
Journal:  Cytometry B Clin Cytom       Date:  2013-09-16       Impact factor: 3.058

3.  The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.

Authors:  W Verbeek; K Vehmeyer; B Wörmann; W Hiddemann
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.